Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference
19 2월 2020 - 6:05AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that the company will present at the
Biomarkers Series UK 2020 conference in Manchester, UK, February
19-20.
The presentation, titled “Maximizing Immunotherapy Biomarker
Discovery with an Advanced Tumor Immunogenomics Platform,” will
describe the Personalis universal cancer immunogenomics platform,
ImmunoID NeXT™. Erin Newburn, MS, PhD, will present for Personalis.
Dr. Newburn will provide an overview of how the platform can be
used to explore critical immunotherapy-related resistance
mechanisms and novel composite biomarkers of response utilizing
analytics including human leukocyte antigen (HLA) typing and HLA
loss of heterozygosity (LOH), neoantigen prediction and load,
immune repertoire characterization, oncoviral detection, as well as
the evaluation of tumor mutational burden (TMB) and microsatellite
instability (MSI) status.
ImmunoID NeXT™ is the first platform to enable comprehensive
analysis of both a tumor and its immune microenvironment from a
single sample. The platform can be used to investigate the key
tumor- and immune-related areas of cancer biology, consolidating
multiple oncology biomarker assays into one and maximizing the
biological information that can be generated from a single tumor
specimen.
Personalis will also be exhibiting during the conference
(Exhibit #38). Representatives will be available to answer
questions about the company’s cancer immunogenomics
capabilities.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200218006062/en/
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024